Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies.

Saved in:
Bibliographic Details
Title: Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies.
Authors: Bayó C; Immunology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain., Castellano G; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain., Marín F; Hereditary Cancer Program, Catalan institute of oncology, IDIBELL, Badalona, Catalunya, Spain.; Consortium for Biomedical Research in Cancer, Carlos III Institute of Health, CIBERONC, Madrid, Comunidad de Madrid, Spain., Castillo-Iturra J; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Ocaña T; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Kumari H; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Pellisé M; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Moreira L; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Rivero L; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Daca-Alvarez M; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Ortiz O; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Carballal S; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Moreira R; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Canet-Hermida J; Hereditary Cancer Program, Catalan institute of oncology, IDIBELL, Badalona, Catalunya, Spain.; Consortium for Biomedical Research in Cancer, Carlos III Institute of Health, CIBERONC, Madrid, Comunidad de Madrid, Spain., Pineda M; Hereditary Cancer Program, Catalan institute of oncology, IDIBELL, Badalona, Catalunya, Spain.; Consortium for Biomedical Research in Cancer, Carlos III Institute of Health, CIBERONC, Madrid, Comunidad de Madrid, Spain., Gabriel C; Hereditary Cancer Program, Catalan institute of oncology, IDIBELL, Badalona, Catalunya, Spain.; Consortium for Biomedical Research in Cancer, Carlos III Institute of Health, CIBERONC, Madrid, Comunidad de Madrid, Spain., Flórez-Grau G; Immunology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain., Juan M; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain.; Immunology, Servei d'Immunologia. Hospital Clínic de Barcelona, Barcelona, Barcelona, Spain., Benitez-Ribas D; Immunology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.; Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain., Balaguer F; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Catalunya, Spain francescbalaguer@ub.edu.; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salud, Universitat de Barcelona (UB), Barcelona, Spain.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Apr 20; Vol. 13 (4). Date of Electronic Publication: 2025 Apr 20.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2024-011177